+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07291037

Randomized Phase III Study Comparing Datopotamab Deruxtecan and Docetaxel in Previously Treated TROP2-Positive Advanced or Metastatic Non-Squamous NSCLC Without Actionable Genomic Alterations

Led by AstraZeneca · Updated on 2026-10-13

400

Participants Needed

206

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of datopotamab deruxtecan Dato-DXd compared with docetaxel in patients who have advanced or metastatic non-squamous non-small cell lung cancer NSCLC that is positive for trophoblast cell surface protein 2 TROP2 and lacks actionable genomic alterations. This phase III study is randomized, open-label, and includes two groups to compare these treatments in participants who have previously received therapy. Participants receive either Dato-DXd or docetaxel through intravenous infusions every three weeks, with each treatment given on the first day of a 21-day cycle. The study also evaluates the performance of an investigational diagnostic device that measures TROP2 levels. This two-arm study runs until disease progression or other discontinuation criteria are met. During the study, participants undergo regular assessments including imaging scans to measure tumor size, laboratory tests to check organ function, and questionnaires related to lung cancer symptoms, physical function, and quality of life. Researchers will monitor progression-free survival and overall survival over approximately 2.5 to 3.5 years, along with secondary outcomes such as response rates and duration of response. Safety and tolerability are also evaluated throughout the trial.

CONDITIONS

Brief Title

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here